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Although thiazide diuretics reduce blood pressure 
as eﬀ ectively as other drugs,1 one of the recognised 
disadvantages of drugs of this class is that they adversely 
aﬀ ect lipid and glucose metabolism.2 They cause a slight 
increase in serum LDL cholesterol and triglycerides, a 
decrease in serum HDL cholesterol, and an increase in 
blood glucose concentrations both in the fasting state 
and after a glucose load. The eﬀ ects on blood glucose 
have raised special concern because data from clinical 
trials have shown that, when prolonged for years, 
thiazide-based treatment is associated with an increased 
incidence of type 2 diabetes compared with placebo or 
with drugs such as blockers of the renin–angiotensin 
system or calcium-channel blockers.3,4 
while leaving the unhealthy ones behind, or the result 
of some other factors.14 One possibility is that it shows a 
lifecycle issue, with migrants beneﬁ ting from the positive 
health eﬀ ects of migration (eg, access to better health 
care, reduced exposure to some types of communicable 
diseases), while the negative eﬀ ects of migration (lifestyle 
diseases, some forms of workplace diseases) are lagging 
because they aﬀ ect migrants much later in their lives. 
If it is indeed a matter of lifecycles, the focus of 
research on migrant health in China should shift 
to trying to understand the entire lifecycle of rural 
migrants, including their changing exposures to various 
health risks, changes of cultural habits and of physical, 
social, and psychological environments, adaptations to 
their new conditions (both eﬀ ective and suboptimum), 
and changes in their health knowledge, perceptions of 
risk, and expectations of health. To prevent an explosion 
of obesity and metabolic diseases in migration-receiving 
cities and countries in the near future, it is clear that 
any action must focus on the agency of the migrants 
themselves. Cultural habits that were positive or neutral 
in a rural context might become problematic after 
migration. It is easy to forget that in most traditional 
rural societies, lean and physically active did not 
connote health and attractiveness, but instead poverty, 
low status, and dependence on low-prestige manual 
labour—all undesirable social traits.15 Similarly, weight 
loss was an alarming sign of deteriorating health, 
not a marker of ﬁ tness. Changing these perceptions 
to adapt to the health ideology of the cities and to a 
more modern conception of health risk will take time 
and understanding. Changing perceptions and habits 
is as diﬃ  cult among migrants as it is for the rest of the 
population, but action must focus on understanding the 
origin of these unhealthy behaviours, their causes, and 
the reasons for their persistence or emergence. 
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Although in some studies drug-induced diabetes has 
not been associated with substantial modiﬁ cation of 
cardiovascular risk,3 in others an increased risk of cardiac 
and cerebrovascular morbid or fatal events has been 
noted,5 leading to the hypothesis that thiazides favour, 
perhaps in predisposed patients, the development 
of a so-called true diabetes—ie, diabetes with all the 
adverse clinical consequences. Some guidelines have 
therefore downgraded thiazides from their earlier 
position as ﬁ rst choice antihypertensives;6 others have 
issued recommendations that discourage the use of 
thiazides in some categories of patients—eg, those with 
metabolic syndrome, in whom the risk of new-onset 
diabetes is substantially higher.2,7
Several possibilities have been investigated to 
determine whether and to what extent the adverse eﬀ ects 
of thiazides on glucose metabolism can be attenuated. 
It is long established that the adverse eﬀ ects of thiazides 
on blood glucose and other metabolic variables increase 
with increasing doses,8 which is why the high diuretic 
doses used previously have been abandoned. Additionally, 
glucose metabolism might be better preserved if thiazides 
are given in combination with blockers of the renin–
angiotensin system—perhaps because the protective 
eﬀ ect of reducing the amount of (or blocking the eﬀ ect 
of) angiotensin II oﬀ sets at least partly the adverse 
thiazide-dependent metabolic consequences.8 
Another option to reduce the adverse eﬀ ects 
of thiazides is to give potassium supplements, a 
strategy that stems from the observation that the 
hyperglycaemic eﬀ ect of thiazide diuretics is enhanced 
by potassium depletion and inversely related to the 
serum potassium concentrations.9 By extension, 
it is possible that the eﬀ ect of thiazides on glucose 
metabolism would also be attenuated by giving them in 
combination with a potassium-sparing diuretic.
In an Article10 by Morris J Brown and colleagues in 
The Lancet Diabetes & Endocrinology, the combination 
of a thiazide and potassium-sparing diuretic is shown 
to be therapeutically valid. Brown and colleagues 
randomly assigned several hundred patients with 
hypertension to 24 weeks double-blind treatment with 
hydrochlorothiazide (25 mg daily), amiloride (10 mg 
daily), or the combination of the two drugs at half doses 
(12·5 mg and 5 mg daily); all doses were doubled after 
12 weeks. The investigators did 2 h oral glucose tolerance 
tests at baseline and at 12 and 24 weeks. Compared with 
baseline, the 2 h blood glucose concentrations increased 
in patients in the hydrochlorothiazide group and 
decreased in those taking amiloride, even when amiloride 
was taken together with hydroclorothiazide (diﬀ erence 
between hydrochlorothiazide and combination groups: 
–0·42 mmol/L [95% CI –0·84 to –0·004]; 0·048). 
Compared with thiazide monotherapy, blood 
pressure reduction (as shown by home blood pressure 
measurements) was not signiﬁ cantly diﬀ erent in 
the amiloride group and was slightly greater in the 
combination group. The number of patients with 
serious side-eﬀ ects was small in all groups and the 
mean increase in serum potassium attributable to the 
potassium-sparing diuretic was negligible.
On the basis of these results, Brown and colleagues 
suggest inclusion of the combination of a low-dose 
thiazide diuretic with amiloride among the ﬁ rst-choice 
treatment strategies recommended for hypertension.10 
This suggestion is legitimate, because the world is 
facing an epidemic of diabetes, and use of diuretic-based 
treatments that do not have dysmetabolic eﬀ ects could 
have far-reaching beneﬁ cial consequences. However, 
before this suggestion is incorporated into guidelines, 
further evidence is needed. A study with longer 
treatment duration than 24 weeks would be useful to 
ensure that the favourable metabolic eﬀ ects of amiloride 
continue to prevail. Although Brown and colleagues 
argue that data about 2 h glucose concentrations can be 
extrapolated to accurately predict the risk of new-onset 
diabetes,11 direct quantiﬁ cation of diabetes development 
in patients given a thiazide diuretic compared with 
those given a thiazide–amiloride combination is needed. 
Finally, and more generally, long-term studies are 
needed to clarify previous discrepancies and provide 
conclusive evidence that the diabetes induced by 
antihypertensive drugs (thiazides and β blockers)3,4 
has the same deleterious eﬀ ects on macrovascular and 
microvascular disease as spontaneous diabetes to be 
sure that the eﬀ ect of the hydrochlorothiazide–amiloride 
combination translates from a trial setting into real-life 
beneﬁ t for cardiovascular prevention for patients.
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Taking action on sugar
On Oct 22, 2015, Public Health England (PHE) published 
its report1 setting out the evidence for eﬀ ective policies 
to reduce sugar intake on a population basis. The report 
followed those from the UK Department of Health‘s 
Scientiﬁ c Advisory Committee on Nutrition (SACN)2 
and WHO,3 both of which concluded that sugar has 
important eﬀ ects on weight gain and dental caries, 
with the authors of the SACN report also noting that 
consumption of sugary soft drinks increase the risk of 
type 2 diabetes independently of the eﬀ ect of sugar 
on weight gain. Both proposed limiting sugar to 5% of 
total dietary energy intake, either for the population 
(SACN2) or individually (WHO3), with SACN specifying 
that consumption of sugary drinks should be greatly 
reduced. The role of sugar in non-alcoholic fatty liver 
disease and other metabolic eﬀ ects of fructose4 were 
not considered.
In some people, especially those who are young 
and socially disadvantaged, sugar intake can be ﬁ ve 
times greater that the proposed 5% limit, partly 
accounting for the huge global burden of obesity5 and 
dental caries6 and the escalating incidence of diabetes 
and other non-communicable diseases in almost all 
countries.7 The international consulting company 
McKinsey estimates that the economic cost of obesity 
worldwide is about US$2 trillion a year, equivalent 
to the cost of all warfare and terrorism.8 There is also 
a huge oversupply of world sugar;9 major plans for 
expansion of sugar production; falling world sugar 
prices; and transnational feed, food, advertising, and 
supermarket companies geared to selling this ever 
cheaper commodity in foods, snacks, and drinks for 
ever greater proﬁ ts. Furthermore big free market 
developments threaten to make the situation worse. 
The European Union (EU) sugar price arrangements will 
end in 2017, allowing sugar to become even cheaper in 
Europe, and if the proposed EU–US international trade 
agreement goes ahead, fructose corn syrup could ﬂ ood 
the EU market. In the Middle East and north Africa, 
countries have been subsidising rather than taxing 
sugar (and vegetable—usually palm—oil) for years,10 
thereby helping to promote their consumption and to 
induce the epidemics of obesity, diabetes, and other 
non-communicable diseases. In view of the expected 
global major escalation in obesity and diabetes, how 
can public health authorities tackle this seemingly 
overwhelming commercial drive? 
In their report,1 PHE concludes that although clinicians 
should advise patients on speciﬁ c dietary changes, the 
pervasive industrial eﬀ ects on consumer choices also 
need to be severely constrained. All forms of marketing 
inﬂ uence food preferences, choices, and purchases for 
adults and children. Food retail price promotions are 
more widespread in Britain than elsewhere in Europe. 
Foods on promotion account for around 40% of all 
expenditure on food and drinks consumed at home. 
Higher sugar products are promoted more than other 
foods. Such promotions can increase purchases by a ﬁ fth, 
especially of sugary products, in all societal groups.1 PHE 
therefore recommends a drastic reduction in sugary food 
promotions, as well as severe restrictions on marketing 
and sponsorship, but does not specify such measures 
